NCT01848041View on ClinicalTrials.gov

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

February 28, 2014

Conditions
Blepharoptosis
Interventions
DRUG

RVL-1201

RVL-1201 0.1% Ophthalmic Solution

DRUG

RVL-1201 Vehicle Placebo

RVL-1201 Vehicle Placebo

Trial Locations (1)

30260

Morrow

All Listed Sponsors
lead

RVL Pharmaceuticals, Inc.

INDUSTRY

NCT01848041 - Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis | Biotech Hunter | Biotech Hunter